Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...
Researchers assessed whether switching to protease inhibitor-based antiretroviral therapy mitigates or reverses weight gain in patients with HIV infection.
GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
On September 10, experts across disciplines, from infectious disease clinicians to regulators to representatives from the pharmaceutical industry, convened at the inaugural ImmunOptimize workshop in ...
Dispatch and carefully placed it inside my copy of And The Band Played On: Politics, People, and the AIDS Epidemic – his most ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback